Asia FX muted, dollar fragile as CPI data boosts Sept rate cut bets
CAMBRIDGE, MA—Benjamin L. Palleiko, Chief Executive Officer of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), sold 6,669 shares of the company’s common stock on March 7, 2025, at a price of $11.97 per share. This transaction amounted to a total value of $79,827. The sale comes as the stock shows strong momentum, with a 10.3% gain over the past week and an impressive 41.56% return year-to-date, according to InvestingPro data.
The sale was conducted to cover tax withholding obligations related to the vesting and settlement of restricted stock units (RSUs). This type of transaction, known as a "sell to cover," is not discretionary and is intended to satisfy tax liabilities.
On March 6, 2025, Palleiko also acquired 15,625 shares through the exercise of RSUs, with no cash consideration involved. Following these transactions, Palleiko holds 287,811 shares of KalVista Pharmaceuticals directly.
KalVista Pharmaceuticals, headquartered in Cambridge, Massachusetts, is a company specializing in pharmaceutical preparations, focusing on innovative treatments within the life sciences sector. With a market capitalization of $593.51 million, the company is scheduled to report earnings on March 12, 2025, and currently maintains a Strong Buy consensus from analysts tracking the stock.
In other recent news, KalVista Pharmaceuticals has shared promising data regarding their investigational drug, sebetralstat, for treating hereditary angioedema (HAE) attacks. The KONFIDENT-S study revealed that sebetralstat could significantly reduce the time to symptom relief, with a median time of 1 hour and 16 minutes, compared to the 2.5 hours needed for existing injectable treatments. KalVista has filed for regulatory approval of sebetralstat in multiple markets, with a U.S. FDA decision expected by June 17, 2025. JMP Securities has maintained a Market Outperform rating on KalVista with a $19 price target, emphasizing the potential of sebetralstat to expand the on-demand treatment market for HAE. Analysts from JMP Securities noted that the availability of an oral treatment could lead to more frequent treatment of attacks, with a survey indicating that two-thirds of doctors believe patients would treat more attacks with such an option. The analysts also highlighted the potential market growth, predicting that HAE medications could see sales increase from $2.8 billion in 2023 to over $6 billion by 2030. KalVista’s sebetralstat, if approved, is positioned to capture a significant share of the market, which is currently dominated by injectable therapies. The company’s focus on addressing unmet needs in HAE treatment through an oral on-demand option is a central element of their strategy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.